Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Lawrence V. Friedrich"'
Autor:
Judith N. Steenbergen, Scott A. Van Wart, Elizabeth A Lakota, M Courtney Safir, Evan Tzanis, Sujata M. Bhavnani, Lawrence V. Friedrich, Christopher M. Rubino, Michael Trang, Paul G. Ambrose
Publikováno v:
Antimicrobial Agents and Chemotherapy
Omadacycline, a novel aminomethylcycline antibiotic with activity against Gram-positive and -negative organisms, including tetracycline-resistant pathogens, received FDA approval in October 2018 for the treatment of patients with acute bacterial skin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bdb94e29135a314464f2ea5f88dfdde
http://europepmc.org/articles/PMC7318031
http://europepmc.org/articles/PMC7318031
Autor:
Elizabeth A Lakota, Haley Conde, Judith N. Steenbergen, Lawrence V. Friedrich, Sujata M. Bhavnani, Jennifer McCauley, Paul G. Ambrose, Brian VanScoy
Publikováno v:
Antimicrobial Agents and Chemotherapy. 64
Omadacycline is a novel aminomethylcycline with activity against Gram-positive and -negative organisms, including Haemophilus influenzae, which is one of the leading causes of community-acquired bacterial pneumonia (CABP). The evaluation of antimicro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b63c528319a4bc59a1d740b3ef27b17e
https://doi.org/10.1128/aac.02265-19
https://doi.org/10.1128/aac.02265-19
Autor:
Rachel L. Soon, Alan Forrest, Patricia N. Holden, Lawrence V. Friedrich, Zackery P Bulman, Judith N. Steenbergen, Justin R. Lenhard, Brian T. Tsuji, Pamela A. Kelchlin
Publikováno v:
International Journal of Antimicrobial Agents. 49:25-30
The proliferation of multidrug-resistant Gram-negative pathogens has been exacerbated by a lack of novel agents in current development by pharmaceutical companies. Ceftolozane/tazobactam was recently approved by the FDA for the treatment of complicat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e2cfed669b49fca9866cacd784d28e7
https://doi.org/10.1016/j.ijantimicag.2016.07.015
https://doi.org/10.1016/j.ijantimicag.2016.07.015
Autor:
Pamela A. Kelchlin, Patricia N. Holden, Brian T. Tsuji, Alan Forrest, Justin R. Lenhard, Rachel L. Soon, Judith N. Steenbergen, Lawrence V. Friedrich, Zackery P Bulman
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:1967-1973
Despite a dearth of new agents currently being developed to combat multidrug-resistant Gram-negative pathogens, the combination of ceftolozane and tazobactam was recently approved by the Food and Drug Administration to treat complicated intra-abdomin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ffff95c2ef00582ddeee7e2c867d891
https://doi.org/10.1128/aac.02635-15
https://doi.org/10.1128/aac.02635-15
Autor:
Kathryn Liolios, Evan Tzanis, Jeffrey P. Hammel, Paul G. Ambrose, Paul C. McGovern, Sujata M. Bhavnani, Michael Trang, Judith N. Steenbergen, Darryl R George, Lawrence V. Friedrich, Christopher M. Rubino
Publikováno v:
Open Forum Infectious Diseases
Background OMC, an aminomethylcycline structurally related to tetracycline agents, was recently approved by the US FDA for the treatment of adult patients with ABSSSI (IV-to-PO and PO regimens) and CABP (IV-to-PO regimen). To better understand exposu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85fa357016ca66368c8b1fae33575a7a
https://doi.org/10.1093/ofid/ofz360.801
https://doi.org/10.1093/ofid/ofz360.801
Autor:
Lawrence V. Friedrich, Judith N. Steenbergen, Evan Tzanis, Paul C. McGovern, Sujata M. Bhavnani, Christopher M. Rubino, Elizabeth A Lakota
Publikováno v:
Open Forum Infectious Diseases
Background Omadacycline is a novel aminomethylcycline with activity against Gram-positive and -negative organisms, including tetracycline-resistant pathogens. Omadacycline was recently approved in the United States for treatment of adult patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6e8fc47bf860394e90947ada3eec98e
http://europepmc.org/articles/PMC6809138
http://europepmc.org/articles/PMC6809138
Autor:
Paul G. Ambrose, Lawrence V. Friedrich, Michael Trang, Brian VanScoy, Sujata M. Bhavnani, Dylan C. Alexander, Haley Conde, Jennifer McCauley-Miller
Publikováno v:
Antimicrobial Agents and Chemotherapy. 61
A major challenge in treating patients is the selection of the “right” antibiotic regimen. Given that the optimal β-lactam/β-lactamase inhibitor pair is dependent upon the spectrum of β-lactamase enzymes produced and the frequency of resistanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc718ed777628145683250487a678375
https://doi.org/10.1128/aac.00630-17
https://doi.org/10.1128/aac.00630-17
Autor:
Amy Manley, Stephen Bai, Lawrence V. Friedrich, Surya Chitra, Evan Tzanis, Judith N. Steenbergen, Lynne Garrity-Ryan, Marla Curran, Bob Noble
Publikováno v:
Open Forum Infectious Diseases
Background Omadacycline (OMC) is an intravenous (IV) and oral aminomethylcycline antibiotic in the tetracycline class approved in the United States to treat acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5db0bfafd51947362366b7779868c650
http://europepmc.org/articles/PMC6811165
http://europepmc.org/articles/PMC6811165
Autor:
Paul G. Ambrose, Olanrewaju O. Okusanya, Alan Forrest, Ronald N. Jones, Catharine C. Bulik, Judith N. Steenbergen, Sujata M. Bhavnani, Rodrigo E. Mendes, Brian VanScoy, Lawrence V. Friedrich, Jennifer McCauley
Publikováno v:
Antimicrobial Agents and Chemotherapy. 57:5924-5930
We recently investigated the pharmacokinetics-pharmacodynamics (PK-PD) of tazobactam in combination with ceftolozane against an isogenic CTX-M-15-producing Escherichia coli triplet set, genetically engineered to transcribe different levels of bla CTX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8fcd93a76b84926c49165d12edb39ca
https://doi.org/10.1128/aac.00656-13
https://doi.org/10.1128/aac.00656-13
Autor:
Brian VanScoy, Paul G. Ambrose, Ronald N. Jones, Catharine C. Bulik, Alan Forrest, Judith N. Steenbergen, Olanrewaju O. Okusanya, Lawrence V. Friedrich, Anthony M. Nicasio, Rodrigo E. Mendes, Sujata M. Bhavnani, Mariana Castanheira
Publikováno v:
Antimicrobial Agents and Chemotherapy. 57:2809-2814
Despite β-lactamase inhibitors being available for clinical use for nearly 30 years, a paucity of data exists describing the pharmacokinetic-pharmacodynamic (PK-PD) determinants of efficacy for these agents. Herein, we describe dose fractionation st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1db93e918a2cb440a8ea4957a637bffc
https://doi.org/10.1128/aac.02513-12
https://doi.org/10.1128/aac.02513-12